SCHEMBL5653004

SCHEMBL5653004

CCOC(=O)c1sc2c(ccc(=O)n2Cc2c(F)cccc2F)c1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 4/20 0.41
HPGD P15428 4/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
HSD17B10 Q99714 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 3/20 0.41
NPC1 O15118 2/20 0.41
PTGDR2 Q9Y5Y4 3/20 0.41
GNRHR P30968 3/20 0.41
MAPK1 P28482 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
CDC7 O00311 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651454 0.87 ALDH1A1 (0.54) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL5651499 0.83 MDM2 (0.51) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL5651409 0.82 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL5648462 0.82 MAPK8 (0.51) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL5650191 0.82 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL5648783 0.81 LMNA (0.45) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL5652931 0.81 ACACB (0.53) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL5650136 0.80 MAPT (0.51) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL5653013 0.80 GABRA1 (0.47) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL5652293 0.80 MAPT (0.44) ALDH1A1KDM4EHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 ALDH1A1 1498/4885KDM4E 3821/4885HPGD 1929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.